CAJ | 학술논문

目的：分析表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼治疗非小细胞肺癌脑膜转移的效果。方法收集我院确诊为非小细胞肺癌脑膜转移患者的病例进行回顾性分析,根据治疗方案将病例分为观察组(鞘内化疗联合厄洛替尼治疗组,17例)和对照组(鞘内化疗组,29例),对两组的治疗效果进行分析。结果观察组的脑脊液癌细胞转阴率为52.9%,对照组的脑脊膜癌细胞转阴率为24.1%,两组比较差异有统计学意义(P<0.05)；观察组症状缓解率为64.7%,对照组的症状缓解率为31.0%,两组比较差异有统计学意义(P<0.05)；观察组中位无进展生存期为5.3个月,对照组中位无进展生存期为3.4个月,两组比较差异有统计学意义(P<0.05)。结论对于非小细胞肺癌脑膜转移,厄洛替尼治疗联合鞘内化疗能够取得较好的治疗效果。
목적：분석표피생장인자수체락안산격매억제제액락체니치료비소세포폐암뇌막전이적효과。방법수집아원학진위비소세포폐암뇌막전이환자적병례진행회고성분석,근거치료방안장병례분위관찰조(초내화료연합액락체니치료조,17례)화대조조(초내화료조,29례),대량조적치료효과진행분석。결과관찰조적뇌척액암세포전음솔위52.9%,대조조적뇌척막암세포전음솔위24.1%,량조비교차이유통계학의의(P<0.05)；관찰조증상완해솔위64.7%,대조조적증상완해솔위31.0%,량조비교차이유통계학의의(P<0.05)；관찰조중위무진전생존기위5.3개월,대조조중위무진전생존기위3.4개월,량조비교차이유통계학의의(P<0.05)。결론대우비소세포폐암뇌막전이,액락체니치료연합초내화료능구취득교호적치료효과。
Objective To analyze the function of Erlotinib in the treatment of non-small cell lung cancer with meningeal metastasis. Methods The cases diagnosed of non small cell lung cancer patients with leptomeningeal metas-tasis in our hospital were collected,and retrospective analysis was done.The patients were divided into observation group (intrathecal chemotherapy combined with Erlotinib treatment group,17 cases) and control group (intrathecal chemothera-py group,29 cases) according to the therapeutic regimen,and the curative effect of the cytologic conversion rate and symptom remission rate of the two groups were analyzed. Results The cytologic conversion rate of the observation group and the control group was 52.9%and 24.1%,and the difference was statistically significant (P<0.05);the symptom remis-sion rate of the observation group and the control group was 64.7% and 31.0%,the difference was statistically signifi-cant (P<0.05);the medianprogression-free survival of the observation group and the control group was 5.3 months and 3.4 months,the difference was statistically significant (P<0.05). Conclusion The Erlotinib combined with intrathecal chemotherapy can effectively improve the curative effect of non small cell lung cancer with meningeal metastasis.